Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Exorex lotion
1305020C0BRAACX
|
Exorex | Tars | Skin | 10,915 |
|
Coal tar solution 5% cutaneous emulsion
1305020C0AACXCX
|
Coal tar/tar (Topical) | Tars | Skin | 2,607 |
|
Psoriderm cream
1305020C0BDABBC
|
Psoriderm (Topical) | Tars | Skin | 729 |
|
Coal tar 6% cream
1305020C0AABCBC
|
Coal tar/tar (Topical) | Tars | Skin | 267 |
|
Coal tar 40% bath emulsion
1305020C0AAABAB
|
Coal tar/tar (Topical) | Tars | Skin | 158 |
|
Psoriderm Emulsion 40% bath additive
1305020C0BDAAAB
|
Psoriderm (Topical) | Tars | Skin | 140 |
|
Coal tar soln 6% / Salicylic acid 2% oint in a base
1305020C0AAFPFP
|
Coal tar/tar (Topical) | Tars | Skin | 49 |
|
Coal tar and Salicylic acid ointment BP
1305020C0AAFLFL
|
Coal tar/tar (Topical) | Tars | Skin | 33 |
|
Coal tar 5% ointment in a base
1305020C0AAAVAV
|
Coal tar/tar (Topical) | Tars | Skin | 26 |
|
Coal tar 10% ointment in a base
1305020C0AABSBS
|
Coal tar/tar (Topical) | Tars | Skin | 23 |
|
Coal tar 6% / Salicylic acid 1% in Emulsifying ointment
1305020C0AAFGFG
|
Coal tar/tar (Topical) | Tars | Skin | 9 |
|
Coal tar 20% in Yellow soft paraffin
1305020C0AAEKEK
|
Coal tar/tar (Topical) | Tars | Skin | 7 |
|
Coal tar solution strong 1% in Emulsifying ointment
1305020C0AAFQFQ
|
Coal tar/tar (Topical) | Tars | Skin | 7 |
|
Coal tar solution strong 5% in Emulsifying ointment
1305020C0AAFIFI
|
Coal tar/tar (Topical) | Tars | Skin | 7 |
|
Coal tar solution strong 2.5% in Emulsifying ointment
1305020C0AAFJFJ
|
Coal tar/tar (Topical) | Tars | Skin | 4 |
|
Calamine and Coal tar ointment
1305020C0AAACAC
|
Coal tar/tar (Topical) | Tars | Skin | 3 |
|
Coal tar 12% / Salicylic acid 3% in White soft paraffin
1305020C0AAGIGI
|
Coal tar/tar (Topical) | Tars | Skin | 3 |
|
Coal tar solution 3% / Salicylic acid 3% in Aqueous cream
1305020C0AAHFHF
|
Coal tar/tar (Topical) | Tars | Skin | 3 |
|
Coal tar 15% in Yellow soft paraffin
1305020C0AAEEEE
|
Coal tar/tar (Topical) | Tars | Skin | 2 |
|
Coal tar 2% in Yellow soft paraffin
1305020C0AADYDY
|
Coal tar/tar (Topical) | Tars | Skin | 2 |
|
Coal tar solution 5% in Emulsifying ointment
1305020C0AAESES
|
Coal tar/tar (Topical) | Tars | Skin | 2 |
|
Coal tar solution 5% in White soft paraffin
1305020C0AAEIEI
|
Coal tar/tar (Topical) | Tars | Skin | 2 |
|
Coal tar 10% / Salicylic acid 5% in Aqueous cream
1305020C0AAFVFV
|
Coal tar/tar (Topical) | Tars | Skin | 1 |
|
Coal tar 12% in White soft paraffin
1305020C0AAELEL
|
Coal tar/tar (Topical) | Tars | Skin | 1 |
|
Coal tar 25% in Yellow soft paraffin
1305020C0AAEFEF
|
Coal tar/tar (Topical) | Tars | Skin | 1 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.